Hypertension in Diabetes Study IV. Therapeutic requirements to maintain tight blood pressure control

Diabetologia

Volumn 39, Issue 12, 1996, Pages 1554-1561

  Stratton, I ^a   Manley, S ^a   Holman, R ^a   Turner, R ^a  

^a NONE

Author keywords

angiotensin converting enzyme; beta blocker; hypertension therapy; non insulin dependent diabetes mellitus

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; METHYLDOPA; NIFEDIPINE; PRAZOSIN;

ADULT; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ATENOLOL; BLOOD PRESSURE; CAPTOPRIL; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; ELECTROLYTES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; HYPOGLYCEMIA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 10544226187     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250050614     Document Type: Conference Paper

References (27)

1. Collins R, Peto R, MacMahon S et al. (1990) Blood pressure, stroke, and coronary heart disease: Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 335: 827-838
2. MRC Working Party (1992) Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 304: 405-412
3. SHEP Cooperative Research Group (1991) Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 265: 3255-3264
4. Dahlöf B, Lindholm L, Hansson L, Schersten B, Ekbom T, Wester PO (1991) Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-Hypertension). Lancet 338: 1281-1285
5. Parving H-H, Anderson AR, Smidt UM, Hommel E, Mathiesen ER, Svendsen PA (1987) Effect of antihypertensive treatment on kidney function in diabetic nephropathy. BJM 294: 1443-1447
6. Mogensen CE (1989) The effect of blood pressure intervention on renal function in insulin-dependent diabetes. Diabète Metab 15: 343-351
7. The Hypertension in Diabetes Study Group (1993) Hypertension in Diabetes Study I: prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 11: 309-317
8. Stern MP, Haffner SM (1991) Dyslipidemia in type 2 diabetes - implications for therapeutic intervention. Diabetes Care 14: 1144-1159
9. Roberts WC (1989) Recent studies on the effects of beta blockers on blood lipid levels. Am Heart J 117: 709-714
10. Pollare T, Lithell H, Selinus J, Berne C (1989) Sensitivity to insulin during treatment with atenolol and propanolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 298: 1152-1157
11. Jarrett RJ, Viberti GC, Argyropoulos A, Hill RD, Mahmud U, Murrells TJ (1984) Microalbuminuria predicts mortality in non-insulin dependent diabetes. Diabet Med 1: 17-19
12. Mogensen CE (1984) Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310: 356-360
13. Mogensen CE, Keane WF, Bennett PH et al. (1995) Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 346: 1080-1084
14. Mogensen CE (1995) Diabetic renal disease: the quest for normotension - and beyond. Diabet Med 12: 756-769
15. Yusuf S (1995) Calcium antagonists in coronary artery disease and hypertension: time for re-evaluation? Circulation 92: 1079-1082
16. Brown P, Baddeley H, Reade AE, Davies JD, McGarry J (1974) Sclerosing peritonitis, an unusual reaction to a beta-adrenergic-blocking drug (practolol). Lancet II: 1477-1481
17. Yusuf S, Peto R, Lewis J, Collins R, Sleight P (1985) Beta blockade during and after myocardial infarction: an overview of the randomised trials. Prog Cardiovasc Dis 27: 335-371
18. Pfeffer MA, Braunwald E, Moyé LA et al. (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 327: 669-677
19. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group (1995) A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 345: 669-685
20. Mathiesen ER, Hommel E, Giese J, Parving H-H (1991) Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ 303: 81-87
21. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. Eng J Med 329: 1456-1462
22. Hypertension in Diabetes Study Group. HDS III (1994) Prospective study of therapy of hypertension in type 2 diabetic patients: efficacy of ACE inhibition and beta-blockade. Diabet Med 11: 773-782
23. UK Prospective Diabetes Study Group (1991) UKPDS VIII. Study design, progress and performance. Diabetologia 34: 877-890
24. UK Prospective Diabetes Study Group (1994) UKPDS XI: Biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects. Diabet Med 11: 534-544
25. SAS Institute (1990) Statistical Analysis System, Version 6. Cary, North Carolina, USA:SAS Institute
26. Rössner S, Taylor CR, Byington RP, Furberg CD (1990) Long term propanolol treatment and changes in body weight after myocardial infarction. BMJ 300: 902-903
27. 1 selectivity rarely matters in clinical practice despite the hype. BMJ 311: 701-702